VolitionRx Launches Nu.Q Vet Cancer Test in Japan Through Fujifilm Vet Systems Partnership

VolitionRx Limited has entered into a supply agreement with Fujifilm Vet Systems Co. Ltd to introduce the Nu.Q Vet Cancer Test to the Japanese market, focusing on early cancer detection in dogs.

The collaboration allows Fujifilm Vet Systems to distribute and conduct cancer screening using the Nu.Q Vet Cancer Test across its extensive network of central reference laboratories in Japan.

Dr. Tom Butera, the CEO of Volition Veterinary Diagnostics Development LLC, expressed excitement about the expansion into Japan, highlighting Fujifilm Vet Systems’ position as a prominent veterinary diagnostic laboratory service in the country.

The Nu.Q Vet Cancer Test is positioned as an accessible and affordable screening tool designed to aid in the early detection of cancer in dogs.

Dr. Jasmine Kway, CEO of Singapore Volition, emphasized the strategic move into the Japanese market as part of the company’s broader Asian expansion plans.

Kiyotaka Fujiwara, the COO of Fujifilm Vet Systems, shared his enthusiasm about introducing the Nu.Q Vet Cancer Test to their diagnostic service offerings, enhancing wellness testing options for Japanese veterinarians.

Volition, with its core research and development activities in Belgium and offices in London, Singapore, and the U.S., is dedicated to advancing the science of epigenetics to improve disease detection and monitoring.

The company’s subsidiary, Belgian Volition SRL, is the contracting party in the agreement with Fujifilm Vet Systems.

Volition’s efforts align with its mission to leverage blood-based tests for early cancer detection and disease monitoring, ultimately enhancing patient outcomes and quality of life.

The company acknowledges the risks associated with its endeavors, including regulatory approvals and market acceptance, as highlighted in its recent filings with the Securities and Exchange Commission.

Nucleosomics™ and Nu.Q®, along with their logos, are trademarks owned by VolitionRx Limited and its subsidiaries.

Volition remains committed to evolving its diagnostic platforms to address critical healthcare needs and contribute to advancements in disease management.

The collaboration with Fujifilm Vet Systems marks a significant milestone in Volition’s mission to make a positive impact in the field of veterinary diagnostics, particularly in the early detection of cancer among dogs.